10:29 AM
Apr 22, 2019
 |  BC Innovations  |  Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma


INDICATION: Brain cancer; sarcoma

Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one human Ewing sarcoma cell line, STAG2 knockout in combination with an shRNA targeting one of five genes involved in dsDNA break repair -- ATR, BRCA1, RAD51, XRCC5 or PRKDC -- decreased...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >